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ABSTRACT
Age at menopause and risk of hysterectomy have strong genetic
components, but the genes involved remain ill defined. We investi-
gated whether genetic variation at the estrogen receptor (ER) gene
contributes to the variability in the onset of menopause in 900 post-
menopausal women, aged 55–80 yr, of the Rotterdam Study, a pop-
ulation-based cohort study in The Netherlands. Gynecological infor-
mation was obtained, and if women reported surgical menopause,
validation of type and indication of surgery was accomplished by
checking medical records. The ER genotypes (PP, Pp, and pp) were
assessed by PCR using the PvuII endonuclease.
Compared with women carrying the pp genotype, homozygous PP
women had a 1.1-yr (P , 0.02) earlier onset of menopause. Further-
more, an allele dose effect was observed, corresponding to a 0.5-yr
(P , 0.02) earlier onset of menopause per copy of the P allele. The
risk of surgical menopause was 2.4 (95% confidence interval, 1.5–3.8)
times higher for women carrying the PP genotype compared to those
in the pp group, with the most prominent effect in women who
underwent hysterectomy due to fibroids or menorrhagia.
We conclude that genetic variations of the ER gene are related to
the onset of natural menopause and the risk of surgical menopause,
especially hysterectomy. (J Clin Endocrinol Metab 84: 3146–3150,
1999)
PREMATURE exposure to low estrogen levels, as occursduring the early onset of menopause, has major im-
plications for the health of postmenopausal women. An early
onset of menopause is associated with a higher risk of car-
diovascular diseases, osteoporosis, and ovarian cancer, and
moreover, it increases the risk of mortality (1–4). Therefore,
from a clinical point of view, it is important to identify factors
that influence the age at menopause. Although several en-
vironmental factors have been proposed as risk factors for
the early onset of menopause (5–9), genetic factors have
recently been proposed to be determinants of age at meno-
pause (10, 11). This idea is strongly supported by a recent
twin study that showed that the onset of menopause is ge-
netically determined, yielding heritability for age at meno-
pause of 63% (12). In addition, undergoing hysterectomy
before reaching natural menopause, with menorrhagia or
fibroids as main indications, showed considerable heritabil-
ity (59%) in the same study.
Several approaches can be followed to identify genes that
might contribute to the variation in the onset of menopause,
including the analysis of candidate genes. In the estrogen
endocrine system the estrogen receptor (ER) is an important
candidate in this respect. This member of the family of ste-
roid transcription factors functions as a regulator of the ex-
pression of many genes and proteins (13, 14), and further-
more, the ER is an important regulator of growth and
differentiation in many tissues, including the endometrium
(15–18).
The aim of the present study was to identify a genetic
determinant of the onset of menopause. We investigated the
association between an anonymous intronic PvuII restriction
fragment length polymorphism (RFLP) of the ER gene and
both the natural and surgical onsets of menopause in a pop-
ulation-based sample of postmenopausal women.
Materials and Methods
All postmenopausal women included in this study were part of a
population-based cohort study (n 5 7983; 61.1% women) of persons
aged 55 yr and over, living in a district of Rotterdam, The Netherlands.
The objective of the study was to investigate the occurrence of chronic
disabling diseases in relation to several potential determinants. Ratio-
nale and design have been described previously (19). A total of 10,275
persons, of whom 9,161 (89%) were living independently, were invited
to participate in the study in 1990. Among those living independently,
the overall response rate was 77% for the home interview and 71% for
examination at the research center, where anthropometric characteristics
and blood samples were taken. The Rotterdam Study was approved by
the medical ethics committee of Erasmus University Medical School, and
written informed consent was obtained from each subject.
For the present study we included independently living subjects who
were initially part of a large epidemiological study of osteoporosis in
which subjects according to the following criteria were excluded: aged
80 yr and over, use of thyroid hormone, use of cytostatics, use of di-
uretics, and known diabetes mellitus type II. Among the 4478 remaining
Received February 3, 1999. Revision received April 28, 1999. Accepted
May 27, 1999.
Address all correspondence and requests for reprints to: Prof. Dr.
H. A. P. Pols, Department of Internal Medicine III, Erasmus University
Medical School, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
E-mail: pols@epib.fgg.eur.nl.
* This work was supported by the Netherlands Organization of Sci-
entific Research (Grant 950–10-618).
0021-972X/99/$03.00/0 Vol. 84, No. 9
The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A.
Copyright © 1999 by The Endocrine Society
3146
 at Medical Library Erasmus MC on December 5, 2006 jcem.endojournals.orgDownloaded from 
independently living subjects, an age-stratified sample of 1000 women
was drawn with balanced numbers (n 5 200) in 5-yr age categories. DNA
samples and menopause data for 900 postmenopausal women were
available for the analysis.
During the home interview each woman provided information on her
reproductive and gynecological history, including ever use of sex ste-
roids. Natural menopause was defined as menopausal after 12 contin-
uous months of amenorrhea, without gynecological surgery or other
procedures that would have stopped menses. In case a gynecological
surgical procedure before natural menopause was reported, we vali-
dated the date and indication of surgery by checking the medical records
of the general practitioner (98% of cases). The health care system in The
Netherlands permits this validation, as every individual has her own
general practictioner. The general practictioner is the only access to
specialist and hospital care and preserves all physician and hospital
notes. Age at menopause was defined as age at natural menopause or
age at surgical menopause (defined as the age at the date of operation).
Surgical procedures were defined as hysterectomy (women with only
hysterectomy and women with hysterectomy plus uni- or bilateral oo-
phorectomy), oophorectomy (women with only uni- or bilateral oopho-
rectomy), and unknown type of gynecological surgery. Smoking habits
(smoking defined as ever vs. never smoked) and socio-economic status
(defined as the highest education level attained; class I–II primary school
with/without lower secondary school vs. class III–IV secondary school
with/without higher vocational school or university) were assessed by
questionnaire. Height and weight were measured at the clinical exam-
ination, with the subject in a standing position without shoes.
Genotyping
The anonymous PvuII RFLP is located in intron 1, 0.4 kb upstream of
exon 2 of the ER gene and was assessed by a PCR procedure (20). Briefly,
genomic DNA (100 ng) was extracted from peripheral leukocytes and
used for PCR amplification in a reaction mixture containing 50 mmol/L
KCl, 10 mmol/L Tris-HCl (pH 8.3), 1.5 mmol/L MgCl2, 0.2 mmol/L
deoxy-NTP, 150 ng of each primer, and 0.2 U Super Taq polymerase (HT
Biotechnology Ltd., Cambridge, UK). The reactions were performed in
a DNA thermocycler (mode 480, Perkin Elmer Corp., Foster City, CA)
with a cycling protocol of 94, 60, and 72 C for 1 min each for 25 cycles.
Ten microliters of PCR products were digested with a PvuII restriction
enzyme (Life Technologies, Inc., Breda, The Netherlands) and 2.5 mL of
a buffer [containing 150 mmol/L Tris-HCl (pH 7.5), 250 mmol/L NaCl,
and 35 mm MgCl2] by incubation for 30 min at 37 C. The digestion
products were analyzed by 1.4% agarose gel electrophoresis in 0.5 3 TBE
(1 3 TBE 5 89 mmol/L Tris, 89 mmol/L boric acid, and 2 mmol/L Na2
ethylenediamine tetraacetate) for 250 volt hours. Separation patterns
were documented by Polaroid photography under UV illumination (302
nm). Genotypes were defined as PP, Pp, or pp. Capital letters denote the
absence and lowercase letters the presence of the site for the restriction
enzyme PvuII (P/p). To confirm the accuracy of the genotyping, re-
peated analysis was performed on 100 randomly selected samples. No
discrepancies were found.
Statistical analysis
One-way ANOVA and x2 analysis were used to compare anthropo-
metric and environmental variables among the three genotype groups.
To account for potential confounders, such as age of menarche, mean
number of offspring, smoking, body mass index, socio-economic status,
hormone replacement therapy, and use of oral contraceptives, we used
multivariate regression models. Subsequently, we calculated the odds
ratio [with 95% confidence interval (CI)] as a measure of the relative risk
for occurrence and indication of surgical menopause associated with ER
genotype using logistic regression models where women without pre-
menopausal gynecological surgery were the reference group. To visu-
alize the genetic influences on the lifetime risk of hysterectomy, we
constructed a cumulative hazard function using the Cox proportional
hazard regression model where women without surgery were the ref-
erence group.
Results
The allele frequencies did not deviate from the Hardy-
Weinberg equilibrium, which indicates that no selection has
occurred among genotypes. Table 1 shows the general char-
acteristics of the postmenopausal women according to their
PvuII genotype. The three genotypes did not differ signifi-
cantly in age at menarche, use of sex steroids (hormone
replacement therapy and oral contraceptives), smoking,
body mass index, and socio-economic status. Furthermore,
the mean number of offspring and the percentage of women
with children did not differ between the three genotypes.
Unfortunately, we did not have data on the total number of
pregnancies, which gives a better insight into fertility.
However, there was a significant difference in the mean
TABLE 1. Characteristics of 900 women according to their ER PvuII genotype
ER PvuII genotype P value
PP Pp pp ANOVA PP vs. pp
No. (%) 205 (23) 435 (48) 260 (29)
Age (yr) 67.9 6 7.0 67.5 6 6.9 67.1 6 7.1 0.4 0.2
Ever use HRT (%) 32 (15.6) 62 (14.2) 37 (14.2) 0.9 0.7
Ever use oral contraceptive (%) 52 (25.4) 106 (24.4) 61 (23.5) 0.9 0.8
Ht (cm) 162.5 6 5.8 161.5 6 6.3 161.7 6 7.3 0.2 0.2
Wt (kg) 68.6 6 10.9 68.4 6 10.0 68.2 6 10.6 0.9 0.5
BMI (kg/m2) 26.0 6 3.8 26.2 6 3.5 26.1 6 4.1 0.7 0.8
Ever smoked (%) 104 (50.7) 228 (52.5) 135 (52.1) 0.9 0.8
SES (education level I–II) (%) 112 (54.6) 258 (59.4) 164 (63.3) 0.2 0.1
No. of offspring 2.2 6 1.6 2.1 6 1.6 2.1 6 1.8 0.6 0.4
Offspring
None (%) 34 (16.6) 85 (19.5) 55 (21.2)
1 or 2 (%) 93 (45.4) 198 (45.5) 116 (44.6) 0.8 0.4
$2 (%) 78 (38.0) 152 (34.9) 89 (34.2)
Age at menopause (yr) 48.1 6 5.0 48.7 6 5.0 49.2 6 4.6 0.06 0.02
Median 49 49 50
Age at natural menopause (yr)a 48.7 6 4.8 49.4 6 4.3 49.8 6 4.2 0.09 0.03
Age at surgical menopause (yr)b 46.1 6 5.5 44.9 6 6.3 46.4 6 4.7 0.4 0.8
Age at menarche (yr) 13.8 6 1.7 13.7 6 1.6 13.6 6 1.7 0.4 0.3
Median 14 14 13
a Natural menopause defined as onset of menopause without hysterectomy, oophorectomy, or any other procedure that stopped menses.
b Age at surgical menopause defined as age at date of hysterectomy and/or oophorectomy.
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age at onset of menopause among the genotypes. The mean
and median age at menopause were 1.1 yr (P , 0.02) earlier
in women with the PP genotype compared to those in the pp
genotype group. Furthermore, an allele-dose effect was ob-
served, corresponding to a 0.5-yr (P , 0.02) earlier onset of
menopause per copy of the P allele. After adjustment for the
potential confounders (age at menarche, mean number of
offspring, use of sex steroids (HRT and oral contraceptives),
smoking, body mass index, and socio-economic status),
similar findings were observed.
After excluding women with artificial menopause, the re-
sult remained essentially the same, with an earlier onset of
natural menopause for the women with the PP genotype.
However, the frequency of women with surgical menopause
differed among the three genotypes (Table 2). Therefore, we
compared the risk of surgical menopause for women by their
ER genotype. The prevalence of women with surgical meno-
pause was highest in women with the PP genotype, lower in
the heterozygous Pp women, and lowest in women with the
pp genotype (Table 2). This overrepresentation was most
notable for the procedure hysterectomy. As shown in Table
2, the overrepresentation of women with surgical menopause
among those with the PP genotype corresponded to a sig-
nificant 2.4 (95% CI, 1.5–3.8) times higher risk compared to
that in women in the reference group with the genotype pp.
When we repeated the analysis by type of surgical proce-
dures, we observed the ER genotype-dependent increased
risk of surgical menopause to be due to hysterectomy and not
oophorectomy. The odds ratios were 1.7 (95% CI, 1.3–2.2) and
0.7 (95% CI, 0.4–1.2)/copy of P allele for hysterectomy and
oophorectomy, respectively. Figure 1 shows the lifetime risk
of hysterectomy according to the estrogen receptor geno-
types as calculated by the Cox proportional hazard function.
The PP group had a significantly higher risk of premeno-
pausal hysterectomy, which confirmed the results from the
logistic regression analysis.
In Table 3 we stratified the analysis by indication for sur-
gery [validated data not available for 91 of 174 (52.3%)
women with surgery]. The predominant indications were
menometrorraghia (23%) and uterus myomatosis (fibroids;
43%). Surgical procedures performed for these indications
were hysterectomy or hysterectomy plus oophorectomy.
There was no oophorectomy solely performed for these in-
dications. We observed that the ER genotype-dependent risk
of hysterectomy to be largely due to the higher frequencies
of the indications menometrorraghia and uterus myomatosis
(fibroids) in the PP genotype group (Table 3). The odds ratios
for the allele dose effect were 2.6 (95% CI, 1.3–5.2) and 1.8
(95% CI 1.1–2.9)/copy of the P allele for menometrorrhagia
and uterus myomatosis, respectively.
Discussion
In this population-based study we show for the first time
that the common allelic variants of the ER gene are associated
with both natural and surgical menopause. Moreover, we
provide evidence that women with the PP genotype will
undergo hysterectomy due to menorrhagia and fibroids
more frequently.
There may have been biases that have lead to incorrect
effect estimates. First, the self-report of the age of menopause
was determined retrospectively, which has been shown to be
unreliable in previous studies (21). Nevertheless, it seems
unlikely that this recall bias differs between the ER geno-
types. Second, although regional differences in the frequency
of hysterectomy have been reported (22–23), it is unlikely
that this would have influenced the relation between the ER
genotype alleles and the risk of surgical menopause in this
FIG. 1. Lifetime risk (percentage) of premenopausal hysterectomy
according to the ER PvuII genotypes. **, P , 0.001 (PP genotype vs.
pp genotype); *, P 5 0.01 (Pp genotype vs. pp genotype; according to
the Cox proportional hazard model).




Surgery (%) 55 (26.8) 84 (19.3) 35 (13.5) 174 (19.3)
Hysterectomy (%)a 49 (23.9) 70 (16.1) 24 (9.2) 143 (15.9)
Ovariectomy (%) 3 (1.5) 12 (2.8) 10 (3.8) 25 (2.8)
Unknown type (%) 3 (1.5) 2 (0.5) 1 (0.4) 6 (0.7)
Odds ratio (95% CI)b Allele dose
Surgery 2.4 (1.5–3.8) 1.5 (1.0–2.4) 1 1.5 (1.2–1.9)
Adjusteda 2.7 (1.6–4.3) 1.7 (1.1–2.7) 1 1.6 (1.3–2.1)
Hysterectomy 3.1 (1.8–5.2) 1.9 (1.1–3.1) 1 1.7 (1.3–2.2)
Ovariectomy 0.4 (0.1–1.7) 0.8 (0.3–1.8) 1 0.7 (0.4–1.2)
a Adjusted for age, age at menopause, age at menarche, number of offspring, use of sex steroids, smoking habits, SES, and BMI.
b The reference group is women without any premenopausal gynecological surgery.
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study. In addition, the allele frequencies of the ER PvuII
polymorphism did not differ from frequencies reported pre-
viously by others and therefore argue strongly against se-
lection bias in our population (24). Third, although the fre-
quencies of missing data on indication differed among the
three genotypes, it is unlikely that the reason for missing
these data differed among the ER genotypes. However, in
view of the low frequency (48%) of validated data on indi-
cation for surgery, confirmation of our observations in an-
other population with more extensive clinical and patholog-
ical data is needed to provide more robust risk estimates
regarding indication. Finally, the ER genotype-dependent
effect on end points of menopause may have biased the
results, because women included in the study were probably
healthier due to the inclusion and exclusion criteria applied.
However, as far as we know, no studies have been published
about the association of the ER gene and any of these criteria.
Moreover, a separate analysis for the total cohort of the
Rotterdam study (n 5 4878 women) did not show a relation
between the inclusion and exclusion criteria and age at
menopause (data not shown).
Evidence that genetic factors are related to age at meno-
pause has been observed previously in family and twin stud-
ies (10–12). However, until now, only a limited number of
genes have been studied in association with the onset of
menopause. One study showed that in a single family four
woman had an interstitial deletion of the long arm of X-
chromosome, which was associated with premature ovarian
failure and premature menopause (25). Furthermore, a link
between menopause and the galactose-1-phosphate uridyl
transferase gene was reported (26). This study, however, had
limited generalizability due to population admixture and the
small number of subjects examined.
In the present study we observed that common variations
of the ER gene are associated with disorders of the uterus.
This supports the hypothesis that a common factor is in-
volved in the pathogenesis of abnormal bleeding and uterine
fibroids (27). The present observation seems logical due to
the fact that the ER has been identified in endometrium,
myometrium, and fibroids (15). In addition, estrogens have
a direct effect on the uterus, which is emphasized by the fact
that ER knockout mice demonstrated lack of uterine response
to estrogen treatment compared to wild-type animals (28).
Although it is unclear how the common allelic variations
of the ER gene influence the action of the ER for its ligand
estradiol, the present study showed an earlier onset of nat-
ural menopause and a higher prevalence of hysterectomy
due to fibroids and menorrhagia in women carrying the P
allele. This suggests a higher responsiveness of this ER gene
allele to estrogen, which might affect the biological response
and ultimately leads to irregularities in the differentiation
and proliferation of endo- and myometrial cells. However, it
must be emphasized that it is presently unclear what is the
molecular mechanism of the association we here report. Be-
cause the PvuII RFLP is an anonymous polymorphism, it
seems likely that the P allele is in linkage disequilibrium with
a truly causative sequence variation elsewhere in the ER gene
or even in another nearby gene. To elucidate the precise
molecular mechanism, extensive sequence analysis and func-
tional studies of the ER gene variants are needed.
In conclusion, we have obtained evidence that a common
allelic variation in the ER gene is associated with age at
menopause as well as hysterectomy. This raises the possi-
bility that genotyping at the polymorphic PvuII ER gene may
provide information on susceptibility to uterine disorders
leading to early onset of menopause, which eventually might
lead to other clinical entities, such as osteoporosis, cardio-
vascular diseases, and ovarian cancer.
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